Shionogi's ensitrelvir shows promise in COVID-19 prevention

Shionogi & Co., Ltd. (TSE:4507) announced positive results from its Phase 3 SCORPIO-PEP trial, revealing that ensitrelvir significantly reduces the risk of developing COVID-19 after exposure. The study demonstrated a 67% relative risk reduction in symptomatic COVID-19 among uninfected individuals treated with ensitrelvir compared to placebo at day 10 (risk ratio: 0.33; 95% CI: 0.22-0.49; p<0.0001). The primary analysis, involving 2,041 household contacts, showed that 2.9% of those treated with ensitrelvir developed symptomatic COVID-19 versus 9.0% in the placebo group. Ensitrelvir has received Fast Track designation from the U.S. FDA for post-exposure prophylaxis of COVID-19. Shionogi plans to continue engaging with regulatory authorities worldwide to bring this novel preventative treatment to market.